TISIDB

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Multi-pass membrane protein
Domain	PF00001 7 transmembrane receptor (rhodopsin family)
Function	Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001503 ossification GO:0002407 dendritic cell chemotaxis GO:0002521 leukocyte differentiation GO:0002548 monocyte chemotaxis GO:0002573 myeloid leukocyte differentiation GO:0002685 regulation of leukocyte migration GO:0002687 positive regulation of leukocyte migration GO:0002688 regulation of leukocyte chemotaxis GO:0002690 positive regulation of leukocyte chemotaxis GO:0002761 regulation of myeloid leukocyte differentiation GO:0002763 positive regulation of myeloid leukocyte differentiation GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006887 exocytosis GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0010959 regulation of metal ion transport GO:0030099 myeloid cell differentiation GO:0030278 regulation of ossification GO:0030279 negative regulation of ossification GO:0030282 bone mineralization GO:0030316 osteoclast differentiation GO:0030335 positive regulation of cell migration GO:0030500 regulation of bone mineralization GO:0030502 negative regulation of bone mineralization GO:0030595 leukocyte chemotaxis GO:0031214 biomineral tissue development GO:0032103 positive regulation of response to external stimulus GO:0036336 dendritic cell migration GO:0040017 positive regulation of locomotion GO:0043270 positive regulation of ion transport GO:0043410 positive regulation of MAPK cascade GO:0045637 regulation of myeloid cell differentiation GO:0045639 positive regulation of myeloid cell differentiation GO:0045670 regulation of osteoclast differentiation GO:0045672 positive regulation of osteoclast differentiation GO:0050900 leukocyte migration GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0051272 positive regulation of cellular component movement GO:0051480 regulation of cytosolic calcium ion concentration GO:0051924 regulation of calcium ion transport GO:0051928 positive regulation of calcium ion transport GO:0055074 calcium ion homeostasis GO:0060326 cell chemotaxis GO:0070098 chemokine-mediated signaling pathway GO:0070167 regulation of biomineral tissue development GO:0070168 negative regulation of biomineral tissue development GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0070838 divalent metal ion transport GO:0071674 mononuclear cell migration GO:0071675 regulation of mononuclear cell migration GO:0071677 positive regulation of mononuclear cell migration GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0090025 regulation of monocyte chemotaxis GO:0090026 positive regulation of monocyte chemotaxis GO:0097529 myeloid leukocyte migration GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2000147 positive regulation of cell motility
Molecular Function	GO:0001637 G-protein coupled chemoattractant receptor activity GO:0001653 peptide receptor activity GO:0004435 phosphatidylinositol phospholipase C activity GO:0004620 phospholipase activity GO:0004629 phospholipase C activity GO:0004896 cytokine receptor activity GO:0004950 chemokine receptor activity GO:0008081 phosphoric diester hydrolase activity GO:0008528 G-protein coupled peptide receptor activity GO:0016298 lipase activity GO:0016493 C-C chemokine receptor activity GO:0019955 cytokine binding GO:0019956 chemokine binding GO:0019957 C-C chemokine binding GO:0035717 chemokine (C-C motif) ligand 7 binding GO:0042578 phosphoric ester hydrolase activity GO:0071791 chemokine (C-C motif) ligand 5 binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04062 Chemokine signaling pathway
Reactome	R-HSA-380108: Chemokine receptors bind chemokines R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-168256: Immune System R-HSA-6783783: Interleukin-10 signaling R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR R-HSA-449147: Signaling by Interleukins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway

Reactome

R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CCR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CCR1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26056232	Breast Carcinoma	Inhibit immunity	Pulmonary metastasis of breast cancer cells is promoted by a distinct population of macrophages, metastasis-associated macrophages (MAMs), which originate from inflammatory monocytes (IMs) recruited by the CC-chemokine ligand 2 (CCL2). We demonstrate here that, through activation of the CCL2 receptor CCR2, the recruited MAMs secrete another chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR1 in macrophages reduces the number of lung metastasis foci, as well as the number of MAMs accumulated in tumor-challenged lung in mice.
29581358	colorectal carcinoma	Promote immunity	Concurrent transcriptome analysis of epithelial cells, stromal cells, and T cell subsets obtained from carcinomatous and normal intestinal samples from patients revealed a distinct gene expression signature in colorectal adenocarcinoma-associated Tregs, with overexpression of CCR1, CCR8, and TNFRSF9, whereas their ligands CCL4 and TNFSF9 were found upregulated in cancerous epithelium.
18645037	Hepatoma	Promote immunity (infiltration)	Tumor-infiltrating DCs expressed chemokine receptors CCR1 and CCR5, and T cells and macrophages expressed CCL3, a ligand for CCR1 and CCR5. Thus, we provide definitive evidence indicating that CCR1 and CCR5 and their ligand CCL3 play a crucial role in the regulation of intratumoral DC accumulation and the subsequent establishment of tumor immunity following induction of tumor apoptosis by suicide genes.
20663902	Hepatocellular Carcinoma	Promote immunity	Deficiency of CCR1 impairs accumulation of CD11c(+), CD4(+), and CD8(+) cells in RFA-treated tumors. Furthermore, in IFN-gamma-enzyme-linked immunospot assay, ECI301 augmented tumor-specific responses after RFA whereas deficiency of CCR1 abolished this augmentation.

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CCR1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CCR1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.622	0.0864
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.307	0.852
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.847	0.46
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.183	0.721
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.463	0.683
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.999	0.457
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.042	0.934
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.217	0.883
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.154	0.925
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.014	0.425
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.065	0.605
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.025	0.884

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CCR1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	1.4	9.7	0.0589
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCR1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CCR1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CCR1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CCR1
Name	chemokine (C-C motif) receptor 1
Aliases	MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CCR1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CCR1